20/20 BioLabs reaches standstill deal on Series E preferred stock

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. RTX
8. SMCI
9. S
10. COF

Go back to 20/20 BioLabs reaches standstill deal on Series E preferred stock

20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock

July 23, 2026 8:31 AM EDT

Agreement Temporarily Restricts Preferred-to-Common Stock Conversions Below a Defined Price Threshold, Mitigating Potential Near-Term Dilution

GAITHERSBURG, Md., July 23, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the Company), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into a standstill agreement (the Agreement) with Streeterville Capital, LLC (Streeterville) relating to the Companys outstanding Series E Convertible Preferred Stock (the Series E Preferred Stock). The Agreement became effective on July 16, 2026.

... More